UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Akt stimulates aerobic glycolysis in cancer cells

Cancer research (Chicago, Ill.), 2004-06, Vol.64 (11), p.3892-3899

2004

Volltextzugriff (PDF)

Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma

Cancer discovery, 2013-09, Vol.3 (9), p.1002-1019

2013

Volltextzugriff (PDF)

Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration

Haematologica (Roma), 2014-07, Vol.99 (7), p.1264-1271

2014

Volltextzugriff (PDF)

The CD28 Signaling Pathway Regulates Glucose Metabolism

Immunity (Cambridge, Mass.), 2002-06, Vol.16 (6), p.769-777

2002

Volltextzugriff (PDF)

Activated Akt promotes increased resting T cell size, CD28‐independent T cell growth, and development of autoimmunity and lymphoma

European journal of immunology, 2003-08, Vol.33 (8), p.2223-2232

2003

Volltextzugriff (PDF)

Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma

Nature medicine, 2015-08, Vol.21 (8), p.922-926

2015

Volltextzugriff (PDF)

Metronomic therapy for refractory/relapsed lymphoma: the PEP-C low-dose oral combination chemotherapy regimen

Hematology (Luxembourg), 2012-04, Vol.17 (sup1), p.s90-s92

2012

Volltextzugriff (PDF)

The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid β-oxidation

Oncogene, 2005-06, Vol.24 (26), p.4165-4173

2005

Volltextzugriff (PDF)

Response assessment in lymphoma: time to lower the bar?

Leukemia & lymphoma, 2013-04, Vol.54 (4), p.673-674

Elstrom, Rebecca L.

2013

Volltextzugriff (PDF)

Interim response assessment for Hodgkin lymphoma: size matters

Leukemia & lymphoma, 2012-11, Vol.53 (11), p.2095-2096

Elstrom, Rebecca L.

2012

Volltextzugriff (PDF)

PET Imaging of Lymphoma

PET clinics, 2012, Vol.7 (1), p.xiii-xiii

2012

Volltextzugriff (PDF)

New Biologic Agents and Immunologic Strategies

Hematology/oncology clinics of North America, 2008-10, Vol.22 (5), p.1037-1049

2008

Volltextzugriff (PDF)

Autologous stem cell transplant is feasible in very elderly patients with lymphoma and limited comorbidity

American journal of hematology, 2012-04, Vol.87 (4), p.433-435

2012

Volltextzugriff (PDF)

Bortezomib in combination with rituximab, dexamethasone, ifosfamide, cisplatin and etoposide chemoimmunotherapy in patients with relapsed and primary refractory diffuse large B-cell lymphoma

Leukemia & lymphoma, 2012-08, Vol.53 (8), p.1469-1473

2012

Volltextzugriff (PDF)

Response to Second-line Therapy Defines the Potential for Cure in Patients With Recurrent Diffuse Large B-Cell Lymphoma: Implications for the Development of Novel Therapeutic Strategies

Clinical lymphoma, myeloma and leukemia, 2010-06, Vol.10 (3), p.192-196

2010

Volltextzugriff (PDF)

Phase 1 study of radiosensitization using bortezomib in patients with relapsed non-Hodgkin lymphoma receiving radioimmunotherapy with 131I-tositumomab

Leukemia & lymphoma, 2015-02, Vol.56 (2), p.342-346

2015

Volltextzugriff (PDF)

FDG-PET in prediction of splenectomy findings in patients with known or suspected lymphoma

Leukemia & lymphoma, 2008-04, Vol.49 (4), p.719-726

2008

Volltextzugriff (PDF)

Trial in progress: A phase III, randomized, open-label study comparing zanubrutinib plus rituximab versus bendamustine plus rituximab in patients with previously untreated mantle cell lymphoma (MCL)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.TPS8071-TPS8071

2020

Volltextzugriff (PDF)

Preliminary results of a phase I trial of FT516, an off-the-shelf natural killer (NK) cell therapy derived from a clonal master induced pluripotent stem cell (iPSC) line expressing high-affinity, non-cleavable CD16 (hnCD16), in patients (pts) with relapsed/refractory (R/R) B-cell lymphoma (BCL)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.7541-7541

2021

Volltextzugriff (PDF)

FDG-PET scans in patients with lymphoma

Current hematologic malignancy reports, 2008-10, Vol.3 (4), p.197-203

2008

Volltextzugriff (PDF)

Phase 1b study of venetoclax plus R- or G-CHOP in patients with B-cell non-Hodgkin lymphoma

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.7566-7566

2016

Volltextzugriff (PDF)

CALGB 50803 (Alliance): A phase II trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.8521-8521

2014

Volltextzugriff (PDF)

Multicenter, phase III, open-label, randomized study in relapsed/refractory CLL to evaluate the benefit of GDC-0199 (ABT-199) plus rituximab compared with bendamustine plus rituximab

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.TPS7120-TPS7120

2014

Volltextzugriff (PDF)

FDG-PET/CT Is Superior to Anatomic Imaging for the Staging and Follow Up of Bony Involvement in Patients with Lymphoma

Blood, 2007-11, Vol.110 (11), p.2330-2330

2007

Volltextzugriff (PDF)

Does FDG-PET/CT Obviate the Need for Standard Diagnostic Contrast-Enhanced CT in Patients with Lymphoma?

Blood, 2007-11, Vol.110 (11), p.2329-2329

2007

Volltextzugriff (PDF)

1 – 25 von 53

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(49)
Mit Volltextzugriff
(41)

Publikationsform

Artikel
(52)
Berichte
(1)

Sprache

Englisch
(53)

Erscheinungsjahr

n.n

Thema

Humans
(23)
Life Sciences & Biomedicine
(20)
Science & Technology
(20)
Hematology
(14)
Oncology
(12)
Female
(10)
Middle Aged
(10)
Adult
(9)
Male
(9)
Aged
(8)
Biological And Medical Sciences
(7)
Lymphoma
(6)
Medical Sciences
(6)
Treatment Outcome
(6)
Disease-Free Survival
(5)
Hematologic And Hematopoietic Diseases
(5)
Aged, 80 And Over
(4)
Fluorodeoxyglucose F18
(4)
Lymphoma, Large B-Cell, Diffuse - Drug Therapy
(4)
Proto-Oncogene Proteins C-Akt
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(19)
Leukemia & Lymphoma
(8)
Journal Of Clinical Oncology
(6)
Haematologica
(2)
Hematology/oncology Clinics Of North America
(2)
Oncogene
(2)
American Journal Of Hematology
(1)
Cancer Discovery
(1)
Cancer Research
(1)
Clinical Lymphoma
(1)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Akt stimulates aerobic glycolysis in cancer cells

Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma

Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration

The CD28 Signaling Pathway Regulates Glucose Metabolism

Activated Akt promotes increased resting T cell size, CD28‐independent T cell growth, and development of autoimmunity and lymphoma

Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma

Metronomic therapy for refractory/relapsed lymphoma: the PEP-C low-dose oral combination chemotherapy regimen

The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid β-oxidation

Response assessment in lymphoma: time to lower the bar?

Interim response assessment for Hodgkin lymphoma: size matters

PET Imaging of Lymphoma

New Biologic Agents and Immunologic Strategies

Autologous stem cell transplant is feasible in very elderly patients with lymphoma and limited comorbidity

Bortezomib in combination with rituximab, dexamethasone, ifosfamide, cisplatin and etoposide chemoimmunotherapy in patients with relapsed and primary refractory diffuse large B-cell lymphoma

Response to Second-line Therapy Defines the Potential for Cure in Patients With Recurrent Diffuse Large B-Cell Lymphoma: Implications for the Development of Novel Therapeutic Strategies

Phase 1 study of radiosensitization using bortezomib in patients with relapsed non-Hodgkin lymphoma receiving radioimmunotherapy with 131I-tositumomab

FDG-PET in prediction of splenectomy findings in patients with known or suspected lymphoma

Trial in progress: A phase III, randomized, open-label study comparing zanubrutinib plus rituximab versus bendamustine plus rituximab in patients with previously untreated mantle cell lymphoma (MCL)

Preliminary results of a phase I trial of FT516, an off-the-shelf natural killer (NK) cell therapy derived from a clonal master induced pluripotent stem cell (iPSC) line expressing high-affinity, non-cleavable CD16 (hnCD16), in patients (pts) with relapsed/refractory (R/R) B-cell lymphoma (BCL)

FDG-PET scans in patients with lymphoma

Phase 1b study of venetoclax plus R- or G-CHOP in patients with B-cell non-Hodgkin lymphoma

CALGB 50803 (Alliance): A phase II trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma

Multicenter, phase III, open-label, randomized study in relapsed/refractory CLL to evaluate the benefit of GDC-0199 (ABT-199) plus rituximab compared with bendamustine plus rituximab

FDG-PET/CT Is Superior to Anatomic Imaging for the Staging and Follow Up of Bony Involvement in Patients with Lymphoma

Does FDG-PET/CT Obviate the Need for Standard Diagnostic Contrast-Enhanced CT in Patients with Lymphoma?

Suchergebnisse filtern